세계의 다발성 경화증 치료 디바이스 시장 : 유형, 치료 디바이스, 최종 사용자 및 지역별(-2032년)

Global Multiple Sclerosis Treatment Devices Market Research Report by Type [Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS)], by Treatment Devices [Electrical Stimulation Devices (Functional Electrical Stimulation (FES), Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS))], by End User (Hospitals & Clinics, Ambulatory Surgical Centers), and by Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Forecast till 2032

Industry Overview

The multiple sclerosis treatment devices market stood at USD 813.58 million and is expected to grow to USD 1,263.87 million by 2032. MS treatment devices refer to medical equipment developed to assist people living with Multiple Sclerosis in coping with muscle weakness, spasticity, balance issues, and chronic pain. They range from neurostimulation devices to robotic gait trainers and functional electrical stimulation systems. By supporting mobility and reducing symptom severity, they complement traditional drug-based therapies.

The Global Multiple Sclerosis (MS) Treatment Devices market is expanding steadily, propelled by rising disease prevalence and innovation in assistive medical technologies. MS affects the central nervous system, with higher cases in North America and Europe. Canada has about 288 cases per 100,000 people.

Modern treatment devices are transforming patient care, particularly advanced neurostimulation tools like spinal cord stimulation (SCS), transcranial magnetic stimulation (TMS), and wearable functional electrical stimulation (FES) systems. These devices enable the patients to regain mobility, decrease spasticity, and alleviate pain. The recent innovations combine AI and sensor-based monitoring, which enable a patient to receive a custom-made therapy that changes according to his or her real-time condition. Smart exoskeletons, robotic-assisted gait trainers, and sensor-embedded textiles are coming up with new opportunities in rehabilitation.

However, still, there are still some barriers that the market is facing due to the conditions of low- and middle-income countries. These include limited awareness, a lack of enough diagnostic infrastructure, and affordability issues. On the other hand, strategic partnerships between hospitals, med-tech companies, and rehabilitation specialists are creating ways to cover this gap. Collaborations are resulting in the creation of smart FES braces, AI-powered pain relief devices, and remote monitoring platforms, which not only reduce hospital visits but also improve treatment compliance. Research, investment, and global health programs are continuing, and these technologies will likely be the main parts of MS management in the future.

Industry Segmentations

The global multiple sclerosis treatment devices market is classified based on the type, comprising primary progressive multiple sclerosis, secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and clinically isolated syndrome.

In terms of the treatment devices, the global market is segmented into electrical stimulation devices and neurostimulation devices. Functional electrical stimulation and transcutaneous electrical nerve stimulation are further segments of the ESD. Spinal cord stimulation and deep brain stimulation are parts of neurostimulation devices.

Based on the end users, the global multiple sclerosis treatment devices market is divided into hospitals & clinics, and ambulatory surgical centers.

Regional Analysis

Demand is largely shaped by consumer preference for premium and durable goods in the North American region. The upholstery sector in the U.S. automotive industry is the major volume driver, while luxury handbags and footwear brands are the main contributors to consumption of higher value. The growth in e-commerce has not only increased the scale but also the geographic scope of niche leather goods producers. Sustainability labeling is becoming a market differentiator.

Craftsmanship, quality, and sustainability are the first and foremost to European buyers. High-end fashion leather production in Italy and France reigns supreme, while Germany's automotive fleet demands precision-processed hides. Green certifications and traceable sourcing are key to market acceptance. Seasonal fashion cycles keep demand steady year-round.

Leather in APAC is required not only for the export of goods but also for the purpose of meeting the needs of growing domestic consumption. China's fashion and automotive markets are hot for mid-to-premium leather products. India balances large-scale export tanning with a rising domestic shoe industry. Technological upgrades in tanning processes are improving quality standards.

Durability and style have made leather the favorite of consumers, particularly in footwear and accessories. The domestic market of Brazil is in line with its export strength, while Argentina is still known for its premium craftsmanship. The shifts in the economy affect the buying power, but the exports hold steady owing to the competitive pricing.

The luxury retail sector in the Gulf states sustains high demand for imported premium leather goods. Africa's emerging middle class is slowly increasing domestic demand. Government incentives in countries like Ethiopia aim to grow local leather processing capacity. However, consumer preference still leans towards imported finished products.

Key Players

Key competitors in the global multiple sclerosis treatment devices market are Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd., Enovis, Bayer, Koninklijke Philips N.V., BTL, and Axonics Inc.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION
• 3.10 INTRODUCTION
• 3.11 DRIVERS
  • 3.11.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS (MS)
  • 3.11.2 ADVANCEMENTS IN NEUROSTIMULATION AND WEARABLE DEVICES
• 3.12 RESTRAINTS
  • 3.12.1 LIMITED AWARENESS AND ACCESSIBILITY IN DEVELOPING REGIONS
• 3.13 OPPORTUNITY
  • 3.13.1 RISING COLLABORATIONS BETWEEN HEALTHCARE PROVIDERS AND TECHNOLOGY FIRMS

4 MARKET FACTOR ANALYSIS

• 4.1 PORTER'S FIVE FORCES MODEL
  • 4.1.1 THREAT OF NEW ENTRANTS
  • 4.1.2 BARGAINING POWER OF SUPPLIERS
  • 4.1.3 THREAT OF SUBSTITUTES
  • 4.1.4 BARGAINING POWER OF BUYERS
  • 4.1.5 INTENSITY OF RIVALRY
• 4.2 IMPACT OF COVID-19 ON THE GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET

5 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY TYPE

• 5.1 OVERVIEW
• 5.2 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
• 5.3 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
• 5.4 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
• 5.5 CLINICALLY ISOLATED SYNDROME (CIS)

6 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY TREATMENT DEVICES

• 6.1 INTRODUCTION
• 6.2 ELECTRICAL STIMULATION DEVICES
  • 6.2.1 FUNCTIONAL ELECTRICAL STIMULATION (FES)
  • 6.2.2 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
• 6.3 NEUROSTIMULATION DEVICES
  • 6.3.1 SPINAL CORD STIMULATION (SCS)
  • 6.3.2 DEEP BRAIN STIMULATION (DBS)

7 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HOSPITALS & CLINICS
• 7.3 AMBULATORY SURGICAL CENTERS

8 GLOBAL MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 FRANCE
  • 8.3.3 UK
  • 8.3.4 SPAIN
  • 8.3.5 ITALY
  • 8.3.6 RUSSIA
  • 8.3.7 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 SOUTH KOREA
  • 8.4.5 MALAYSIA
  • 8.4.6 THAILAND
  • 8.4.7 INDONESIA
  • 8.4.8 REST OF ASIA PACIFIC
• 8.5 SOUTH AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 MEXICO
  • 8.5.3 ARGENTINA
  • 8.5.4 REST OF SOUTH AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 GCC COUNTRIES
  • 8.6.2 SOUTH AFRICA
  • 8.6.3 REST OF MEA

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS, 2023
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.1.1 PRODUCT LAUNCH
  • 9.1.2 PRODUCT APPROVAL

10 COMPANY PROFILES

• 10.1 ENOVIS
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 AXONICS, INC.
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 KEY STRATEGIES
• 10.3 KONINKLIJKE PHILIPS N.V.
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 SWOT ANALYSIS
  • 10.3.6 KEY STRATEGIES
• 10.4 BTL
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 BAYER AG
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 KEY STRATEGY
• 10.6 MEDTRONIC
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 ABBOTT
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 BOSTON SCIENTIFIC CORPORATION
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 BIOTRONIK
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 SALUDA MEDICAL PTY LTD.
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 KEY STRATEGIES

11 DATA CITATIONS

• 11.1 DATA CITATIONS